← All trials
NCT04495374
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 2, 2019
- Primary completion
- Dec 30, 2020
- Completion date
- Apr 2, 2021
- First posted
- Jul 31, 2020
- Last posted
- Jul 31, 2020
- Enrollment
- 102
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Universidade Federal de AlfenasLead sponsor
- Universidade Federal de AlfenasReponsible party - principal investigator
- Universidade Federal de AlfenasOverall official - principal investigator
- Universidade Federal de AlfenasStudy chair
- Santa Casa de AlfenasStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.